Accolate Articles
Par Pharma in deal with AstraZeneca for generic Accolate; J&J unit sues Mylan and Lupin over Prezista
24 November 2010
Mylan confirms first-to-file patent challenge to Cephalon’s sleep-disorder drug Nuvigil
12 January 2010
FDA investigates suicide link with Singulair
7 April 2008
AstraZeneca sales rise 6.9% in 2nd quarter
5 August 2002
Dr Reddy's gets Indian OK for zafirlukast
28 January 2002
Dr Reddy's gains zafirlukast OK in India
7 January 2002
Dr Reddy's gains zafirlukast OK in India
20 December 2001
AstraZeneca sales rise 8%, Nexium doing well
26 July 2001
AstraZeneca hit by slip in Losec sales
26 April 2001
AstraZeneca aims to expand in Japan
12 February 2001
AstraZeneca issues sales and profits slowdown warning
8 February 2001
Morepen looks to grow in the USA
2 February 2001
AstraZeneca's Seroquel approved in Japan
14 December 2000
AstraZeneca sees 17% 1st qtr pretax growth
3 May 2000
AstraZeneca full-year profits up 20% as new products come good
24 February 2000
Astra and Zeneca arms to merge in Japan
7 December 1999
Flovent outperforms Accolate in asthma study
2 November 1999
Accolate approved for young children in USA
23 September 1999
News of Zeneca's Accolate
29 April 1999
Zeneca consolidates Thai business
9 March 1999
Zeneca shows confidence on Astra merger; reports good 1998 results
17 February 1999
Zeneca invests in "superstatin" facility
16 February 1999
Zeneca files for Accolate in Japan
24 December 1998
AstraZeneca's Effect On Rest Of Pharma Sector
17 December 1998
Merck & Co Warns Of Rare Side Effect With Singulair
8 December 1998
Zeneca Files Supplemental NDA with FDA for Pediatric Accolate
19 November 1998
Nolvadex Approval Puts Zeneca On A High
19 November 1998
Zeneca Pharma Sales High But Disappoints Overall
29 October 1998
Zeneca's Zafirlukast Launched In Italy
28 October 1998
Zeneca Profits Decline, But Underlying Growth Strong
6 August 1998
Correction
27 July 1998
UK Pharma Leaders Outline Strategy
22 June 1998
Vanguard Looks Back On Successful 1997
19 March 1998
Good Earnings Growth At Zeneca Despite Strong L
5 March 1998
European Asthma Market Forecasts
25 February 1998
Merck's Singulair Cleared In USA For Asthma
24 February 1998
Pharma Sector Boosts Zeneca 1997 Performance
28 January 1998
Zeneca Upgraded By Goldman Sachs
27 January 1998
Broker Upgrades Zeneca On Acquisition And New Product Outlook
13 January 1998
Lehman Upgrades Euro Pharmaceutical Sector
12 January 1998
1997: Another Good Year For New Chemical Entities
6 January 1998
Merck's Singulair Reaches The Market
5 January 1998
Zeneca To Invest $15 Million In Additional Production Capacity
12 December 1997
Zeneca Allays Fears Of Near-Term Product Gap
4 December 1997
Zeneca Nine-Month Sales Decline
30 October 1997
Second Approval For Merck's Singulair
4 September 1997
Zeneca Sees Strong Growth Against The Odds
8 August 1997
Upbeat UK Companies At Goldman Sachs Conference
17 June 1997
Merck's Singulair Shows Promise In Asthma
30 May 1997
Product Launch Costs Restrain Zeneca's Margins
17 March 1997
First Launch Of Abbott's Zileuton, In USA
3 February 1997
Record Number Of New Chemical Entities In 1996
20 January 1997
Product News In 1996 Dominated By CNS
23 December 1996
EUROPEAN AND LONDON STOCK COMMENT
25 November 1996
US Launch Of Zeneca's Accolate
18 November 1996
Zeneca Shows Its Strength At Nine Months Stage
4 November 1996
Accolate Cleared In USA For Asthma; 1st In Class
7 October 1996
EUROPEAN STOCK COMMENT
7 October 1996
Sales Team Expands At Bristol-Myers Squibb
16 September 1996
Strong Fundamentals On Show At Zeneca
19 August 1996
Zeneca Reports Accolate Plans
3 June 1996
Hiccup For Zeneca With FDA Panel Accolate Verdict
8 April 1996
European Stock Comment
8 April 1996
Zeneca: Prey Or Predator? Analysts Review Company
12 February 1996
Zeneca Reveals Typically Strong Pipeline
18 December 1995
Fast growth In World asthma Market
27 November 1995
Hold Up For Abbott As FDA Says No To Zileuton Dossier
30 October 1995
Fisons Bows To Rhone-Poulenc Rorer L1.8B Offer
16 October 1995
Zeneca's Accolate
4 September 1995
1st Launch For Ono's Pranlukast; In Japan
17 July 1995
Merck pipline report
3 July 1995
Zeneca Files Dossier In UK For Accolate
3 July 1995
Good Performance Forecast For Euro Drugmakers
26 June 1995
Casodex Tolerability Advantage Over Eulexin?
5 June 1995
European STOCK COMMENT
24 April 1995
FDA Panel Backs Abbott's Leutrol For Asthma
17 April 1995
Phase III Results With Zeneca's Accolate
13 March 1995
Zeneca Gets First Approval For Casodex
6 March 1995
PH II RESULTS OF PROSCAR BALDNESS TRIALS
25 April 1994
ZENECA'S PIPELINE ON TARGET AS TENORMIN SLIPS
14 March 1994
ZENECA OPENS NEW PLANT
5 July 1993
ZENECA'S ACCOLATE EFFECTIVE IN ASTHMA
19 April 1993
TENORMIN DRAGS DOWN ZENECA AS IT DEMERGES
8 March 1993
ZENECA FILES 1ST NDA FOR MERREM
4 January 1993
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
